Please Wait
Applying Filters...
menu
    • menu
    Granules India Limited has high volume world-class facilities for APIs, PFIs, & FDFs, serving customers in over 80 countries.

    Virtual Booth

    Contact Supplier

    Jai Radhe Sales is your partner for all your sourcing needs.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2024-10-07

    Virtual Booth

    Contact Supplier

    Egis is a Hungarian generic pharma company with 110 years history. Our activities incorporate all areas of the pharma value chain.

    Virtual Booth

    Contact Supplier

    Biophore is a research-driven global pharmaceutical company focused on niche APIs for the generic industry.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2024-10-07

    Virtual Booth

    Contact Supplier

    Menu

    Tipelukast

    DEVELOPMENTS

    DIGITAL CONTENT

    PharmaCompass
    Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    MediciNova: Two Poster Presentations On MN-001 For Cardiometabolic At EAS
    MediciNova: Two Poster Presentations On MN-001 For Cardiometabolic At EAS

    28 May 2024

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2024/05/28/2888826/7767/en/MediciNova-Announces-Two-Poster-Presentations-at-the-92nd-EAS-Congress-2024-the-Annual-Meeting-of-the-European-Atherosclerosis-Society-Regarding-the-Use-of-MN-001-Tipelukast-for-Ca.html

    GLOBENEWSWIRE
    28 May 2024
    Share Share
    X4 Pharmaceuticals Announces Proposed Public Offering
    X4 Pharmaceuticals Announces Proposed Public Offering

    06 Dec 2022

    // GLOBENEWSWIRE

    https://www.globenewswire.com//news-release/2022/12/06/2568859/0/en/X4-Pharmaceuticals-Announces-Proposed-Public-Offering.html

    GLOBENEWSWIRE
    06 Dec 2022
    Share Share
    MediciNova Receives a Notice of Allowance for a New Patent MN-001 and MN-002
    MediciNova Receives a Notice of Allowance for a New Patent MN-001 and MN-002

    13 Sep 2022

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2022/09/13/2515539/7767/en/MediciNova-Receives-a-Notice-of-Allowance-for-a-New-Patent-Covering-MN-001-and-MN-002-for-the-Treatment-of-Hypertriglyceridemia-Hypercholesterolemia-and-Hyperlipoproteinemia-in-Can.html

    GLOBENEWSWIRE
    13 Sep 2022
    Share Share
    MediciNova's MN-001 Abstract Improves Serum Lipid Panel in T2D and NAFLD
    MediciNova's MN-001 Abstract Improves Serum Lipid Panel in T2D and NAFLD

    09 Aug 2022

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2022/08/09/2495425/7767/en/MediciNova-Announces-MN-001-tipelukast-Abstract-regarding-Improvement-of-Serum-Lipid-Panel-in-Type-2-Diabetes-and-NAFLD-Patients-Accepted-for-Presentation-at-the-IDF-2022-Congress-.html

    GLOBENEWSWIRE
    09 Aug 2022
    Share Share
    MediciNova Announces Initiation of a PII Trial of MN-001 in NAFLD
    MediciNova Announces Initiation of a PII Trial of MN-001 in NAFLD

    26 Jul 2022

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2022/07/26/2485685/7767/en/MediciNova-Announces-Initiation-of-a-Phase-2-Trial-of-MN-001-tipelukast-in-NAFLD-with-Type-2-Diabetes-Mellitus-and-Hypertriglyceridemia.html

    GLOBENEWSWIRE
    26 Jul 2022
    Share Share
    MediciNova Announces MN-001 Research Collaboration with The Juntendo University
    MediciNova Announces MN-001 Research Collaboration with The Juntendo University

    22 Jun 2022

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2022/06/22/2467556/7767/en/MediciNova-Announces-MN-001-tipelukast-Research-Collaboration-with-The-Juntendo-University-School-of-Medicine-in-Tokyo-Japan.html

    GLOBENEWSWIRE
    22 Jun 2022
    Share Share